Literature DB >> 16831032

Inflammatory myofibroblastic tumor with thrombocytosis and a unique chromosomal translocation With ALK rearrangement.

Bonnie Cole1, Holly Zhou, Nancy McAllister, Zeinab Afify, Cheryl M Coffin.   

Abstract

We describe a case of inflammatory myofibroblastic tumor with an unusual constellation of clinical, pathologic, and genetic findings. A 7-year-old girl had an 11-cm abdominopelvic mass accompanied by thrombocytosis, anemia, elevated erythrocyte sedimentation rate, and elevated C-reactive protein. The inflammatory myofibroblastic tumor displayed unusual histologic features of zonal coagulative necrosis, high cellularity with a herringbone pattern, and tumor-associated osteoclast-like giant cells. The complex tumor karyotype included a translocation t(1;2)(q21; p23). Following resection, the laboratory abnormalities resolved. The patient is well and free of recurrence at 3 years following resection. This case raises interesting questions about clinical, pathologic, prognostic, and molecular genetic interrelationships in inflammatory myofibroblastic tumor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16831032     DOI: 10.5858/2006-130-1042-IMTWTA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  4 in total

1.  Recurrent inflammatory myofibroblastic tumor of the inguinal region: A case report and review of the literature.

Authors:  Tian Zhang; Yawei Yuan; Chen Ren; Shasha DU; Jiarong Chen; Quanquan Sun; Zhengjun Liu
Journal:  Oncol Lett       Date:  2015-05-29       Impact factor: 2.967

Review 2.  Inflammatory myofibroblastic tumor of the bladder in children: what can be expected?

Authors:  C H Houben; A Chan; K H Lee; Y H Tam; K F To; W Cheng; C K Yeung
Journal:  Pediatr Surg Int       Date:  2007-04-19       Impact factor: 1.827

3.  An Unusual Case of Systemic Inflammatory Myofibroblastic Tumor with Successful Treatment with ALK-Inhibitor.

Authors:  Sanjivini V Jacob; John D Reith; Angerika Y Kojima; William D Williams; Chen Liu; Lizette Vila Duckworth
Journal:  Case Rep Pathol       Date:  2014-06-18

4.  SPP1 overexpression is associated with poor outcomes in ALK fusion lung cancer patients without receiving targeted therapy.

Authors:  Xiaolin Ji; Yan Liu; Fang Mei; Xinyang Li; Mengxue Zhang; Buwen Yao; Rui Wu; Jiangfeng You; Fei Pei
Journal:  Sci Rep       Date:  2021-07-07       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.